Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Altered brown fat thermoregulation and enhanced cold-induced thermogenesis in young, healthy, winter-swimming men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Altered brown fat thermoregulation and enhanced cold-induced thermogenesis in young, healthy, winter-swimming men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Neprilysin inhibition increases glucagon levels in humans and mice with potential effects on amino acid metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The regulation of circulating hepatokines by fructose ingestion in humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Lack of interleukin-6 (IL-6) leads to expansion of adipose tissue mass in rodents and humans. The exact underlying mechanisms have not been identified. In this placebo-controlled, non-randomized, participant-blinded crossover study, we use the IL-6 receptor antibody tocilizumab to investigate the role of endogenous IL-6 in regulating systemic energy metabolism at rest and during exercise and recovery in lean and obese men using tracer dilution methodology. Tocilizumab reduces fatty acid appearance in the circulation under all conditions in lean and obese individuals, whereas lipolysis (the rate of glycerol appearance into the circulation) is mostly unaffected. The fact that fatty acid oxidation is unaffected by IL-6 receptor blockade suggests increased re-esterification of fatty acids. Glucose kinetics are unaffected. We find that blocking endogenous IL-6 signaling with tocilizumab impairs fat mobilization, which may contribute to expansion of adipose tissue mass and, thus, affect the health of individuals undergoing anti-IL-6 therapy (Clinicaltrials.gov: NCT03967691).

OriginalsprogEngelsk
Artikelnummer100396
TidsskriftCell reports. Medicine
Vol/bind2
Udgave nummer9
Sider (fra-til)100396
ISSN2666-3791
DOI
StatusUdgivet - 21 sep. 2021

Bibliografisk note

© 2021 The Authors.

ID: 68349002